Global marketsUpdated November 4
Novo raises its full-year forecast again.
Novo Nordisk has raised its full-year forecast again, with the new Wegovy pill and older weight-loss shots both helping lift the outlook. Bloomberg says sales of the pill beat estimates; the Financial Times separately reports that demand for GLP-1 products was higher than expected. The new tablet is the striking part, but it isn't carrying the forecast by itself: Novo's older shots helped too.
3 publishers3 reports
Coverage started November 4